Aubagio and Gilenya drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among 400 people who take Aubagio and Gilenya. Common interactions include muscle spasticity among females, and diarrhoea among males.
The phase IV clinical study analyzes what interactions people who take Aubagio and Gilenya have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
400 people who take Aubagio and Gilenya together, and have interactions are studied.
What is Aubagio?
Aubagio has active ingredients of teriflunomide. It is used in multiple sclerosis. Currently, eHealthMe is studying from 49,303 Aubagio users.
What is Gilenya?
Gilenya has active ingredients of fingolimod. It is used in multiple sclerosis. Currently, eHealthMe is studying from 110,620 Gilenya users.
Number of Aubagio and Gilenya reports submitted per year:
Aubagio and Gilenya drug interactions by gender *:
Aubagio and Gilenya drug interactions by age *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Aubagio and Gilenya?
Personalize this study to your gender and ageHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Drug side effects by duration, gender and age:
- Aubagio side effects (49,303 reports)
- Gilenya side effects (110,620 reports)
Common Aubagio drug interactions:
- Aubagio and Ampyra: 3,719 reports
- Aubagio and Vitamin d: 2,799 reports
- Aubagio and Baclofen: 2,536 reports
- Aubagio and Gabapentin: 2,429 reports
- Aubagio and Vitamin d3: 1,343 reports
- Aubagio and Lisinopril: 1,026 reports
- Aubagio and Tecfidera: 1,005 reports
- Aubagio and Aspirin: 964 reports
- Aubagio and Vitamin b12: 931 reports
- Aubagio and Copaxone: 894 reports
Browse interactions between Aubagio and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zCommon Gilenya drug interactions:
- Gilenya and Vitamin d: 6,228 reports
- Gilenya and Baclofen: 4,848 reports
- Gilenya and Ampyra: 3,978 reports
- Gilenya and Gabapentin: 3,584 reports
- Gilenya and Vitamin b12: 1,967 reports
- Gilenya and Vitamin d3: 1,936 reports
- Gilenya and Fingolimod: 1,697 reports
- Gilenya and Lyrica: 1,673 reports
- Gilenya and Ibuprofen: 1,655 reports
- Gilenya and Ibu: 1,645 reports
Browse interactions between Gilenya and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on teriflunomide and fingolimod (the active ingredients of Aubagio and Gilenya, respectively), and Aubagio and Gilenya (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Aubagio and Gilenya.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Levitra and Echinacea drug interaction - 4 seconds ago
- Desoxyn and Fluid Retention - 9 seconds ago
- Compazine and Bleeding Disorders - 20 seconds ago
- Lorazepam and Small Intestinal Perforation - 24 seconds ago
- Dramamine and Muscle Weakness Aggravated - 27 seconds ago
- Pitavastatin and Nausea Aggravated - 29 seconds ago
- Flax Seed Oil and Cortisone Acetate drug interaction - 33 seconds ago
- Sonata and Meclizine drug interaction - 33 seconds ago
- Lovastatin and Praluent drug interaction - 37 seconds ago
- Glucophage and Oesophageal Reflux Aggravated - 43 seconds ago